Tag:
Calistoga Pharmaceuticals
Latest Headlines
Latest Headlines
Gilead's Calistoga buyout marks effort to make cancer a chronic condition
Gilead has been hugely successful developing new drug cocktails that allow patients to manage HIV over the long term. And now it's signaling with its $600 million deal to buy Calistoga
Gilead nabs Calistoga with $600M buyout deal
Calistoga Pharmaceuticals CEO Carol Gallagher ( photo ) has been a passionate advocate for the company's mid-stage, delta-specific PI3K cancer program. And today Gallagher proved just how persuasive
Calistoga banks $40M Series C for pivotal trial work
Seattle-based Calistoga Pharmaceuticals-- a 2009 Fierce 15 company --has banked a $40 million venture round, bringing its four-year take to $100 million. The money will be used to further its lead
Calistoga investors return for $30M Series B
Seattle-based Calistoga Pharmaceuticals has kept the faith with its Series A investors, bringing them back for a $30 million second round. Frazier Healthcare Ventures, Alta Partners, Three Arch
